Skip to main content
. 2022 Sep 2;13:958136. doi: 10.3389/fphar.2022.958136

FIGURE 4.

FIGURE 4

Anti-PLA2R antibody levels (mean ± SEM) at baseline (month 0) and at different time points after Rituximab administration in males and females considered separately. Between-group changes in antibody titer at different time points versus baseline never differed significantly.